TICH 2 Trial
Start date:October 2013 End date:
February 2018 Co-ordinated by:
University of Nottingham Main trial site:
http://tich-2.org
Tranexamic Acid for Hyperacute Primary IntraCerebral Haemorrhage
Aim
To assess whether tranexamic acid is safe and reduces death and dependency after hyperacute (within 8 hours of onset) spontaneous intracerebral haemorrhage.
Trial Design
A phase III prospective pragmatic double blind randomised placebo controlled trial
Chief Investigator
Dr Nikola Sprigg (Medical expert) Clinical Associate Professor, University of Nottingham
Principal Investigator
Professor Rustam Al-Shahi Salman, Professor of clinical neurology, University of Edinburgh & NHS Lothian
Local lead in ED
Dr Matt Reed is the local contact for recruitment of ED patients into the study.
Research Team
- EMERGE Research team
- Stroke Research Group
Eligibility criteria (summary)
Patients who present to the ED within 8 hours of acute spontaneous intracerebral haemorrhagic stroke.
Further information
For more information please refer to main trial website
Research Team
Dr Matt Reed
Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine
Bernadette Gallagher
Senior Research Nurse
More EMERGE Trials
ATTEST2 Trial
Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
NOVEL Study
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions
To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.
PRECISE-CTCA Trial
To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.